Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Aimmune Therapeutics, Inc. | d932346ds1.htm |
| EX-10.4 - EX-10.4 - Aimmune Therapeutics, Inc. | d932346dex104.htm |
| EX-10.3 - EX-10.3 - Aimmune Therapeutics, Inc. | d932346dex103.htm |
| EX-3.3 - EX-3.3 - Aimmune Therapeutics, Inc. | d932346dex33.htm |
| EX-10.2 - EX-10.2 - Aimmune Therapeutics, Inc. | d932346dex102.htm |
| EX-10.5(A) - EX-10.5(A) - Aimmune Therapeutics, Inc. | d932346dex105a.htm |
| EX-10.5(B) - EX-10.5(B) - Aimmune Therapeutics, Inc. | d932346dex105b.htm |
| EX-10.13 - EX-10.13 - Aimmune Therapeutics, Inc. | d932346dex1013.htm |
| EX-21.1 - EX-21.1 - Aimmune Therapeutics, Inc. | d932346dex211.htm |
| EX-10.5(D) - EX-10.5(D) - Aimmune Therapeutics, Inc. | d932346dex105d.htm |
| EX-3.1 - EX-3.1 - Aimmune Therapeutics, Inc. | d932346dex31.htm |
| EX-10.5(C) - EX-10.5(C) - Aimmune Therapeutics, Inc. | d932346dex105c.htm |
| EX-10.1 - EX-10.1 - Aimmune Therapeutics, Inc. | d932346dex101.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Aimmune Therapeutics, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
San Francisco, CA
July 6, 2015